D D S 2020 DIGITAL - Pulmonary Vascular Research Institute
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
P VRI
Pulmonary Vascular
Research Institute
D D S 2020
DIGITAL Date // 24-29 June 2020
24-28 June: Release of recorded
presentations
29 June: 15:00 BST
Live webinar
PVRI Drug Discovery & Development Symposium on Pulmonary Hypertension
// Paul Hassoun, Allan Lawrie & Anna Hemnes
PVRI
Pulmonary Vascular
Research Institute
D D S 2020
DIGITAL
PVRI Drug Discovery & Development Symposium
on Pulmonary Hypertension
Welcome to our DDS 2020 Digital Online Symposium, which we hope you
find informative and enjoyable in equal measure.
In light of the global health and safety recommendations, we are delivering our Symposium
in a digital format due to the current worldwide coronavirus pandemic. Presentations will
be released daily from 24-28 June 2020 and lead to a live webinar on 29 June 2020.
There is plenty of time allocated for Q&A and feedback during this live session and we
encourage you all to join us online.
Registration is free and open to all.
Our Scientific Planning Committee...
Gérald Simonneau Marc Humbert Ardeschir Ghofrani Steeve Provencher
• Hopitaux Universitaires • Université Paris-Sud, • Justus-Liebig-University • University Institute of Cardiology
Paris-Sud, France Giessen, and Pneumology of Quebec,
France Germany Canada
PVRI
Pulmonary Vascular
Research Institute
Our keynote speakers during the live webinar
on 29 June 2020 are...
D D S 2020
Ardeschir Ghofrani Kathryn Hall
Presentation: // Clinical study of inhaled GB002 for treatment of WHO Group I pulmonary arterial Presentation: // Pharmacogenomics and placebo
hypertension (PAH) (NCT03926793) response in a randomised clinical
Sponsor: // Gossamer Bio trials
Talk: // 15:00 - 15:20 BST Talk: // 16:20 - 16:40 BST
DIGITAL
Q&A: // 15:20 - 15:40 BST Q&A: // 16:40 - 17:00 BST
Dr Ardeschir Ghofrani is Professor of Pulmonary Vascular Research at Justus-Liebig-University Giessen, Dr. Kathryn Hall is Associate Molecular Biologist
and Head of the Pulmonary Hypertension Division at the University Hospital in Giessen, Germany. and Assistant Professor in the Division of Preventive
He leads a translational research group on development of new therapeutics for cardiopulmonary vascular Medicine at Brigham and Women’s Hospital and
disease and is a member of the steering committee of the Excellence Cluster Cardio-Pulmonary System Director of Placebo Genetics in the Program in Placebo
(www.eccps.de). He is also a founding member of the Pulmonary Vascular Research Institute Studies hosted at Beth Israel Deaconess Medical Center.
(www.pvrinstitute.org). He has participated in the development of several therapeutics for chronic lung diseases After receiving her PhD in Microbiology and Molecular Genetics
and pulmonary hypertension, including prostanoids, phosphodiesterase inhibitors, endothelin receptor from Harvard University she spent 10 years in the biotech industry
antagonists, tyrosine kinase inhibitors and stimulators of the soluble guanylate cyclase. Professor Ghofrani has tackling problems in drug discovery and development, first at Wyeth
received four awards for investigations in pulmonary vascular science, is a Fellow of the European Respiratory (now Pfizer) and then at Millennium Pharmaceuticals (now Takeda), where she
Society (FERS) and a reviewer for several medical scientific journals. He has also received the Federal became an Associate Director of Drug Development. Dr. Hall returned to Harvard Medical School in 2010,
President’s Award for Innovation and Technology (Deutscher Zukunftspreis). joining the Fellowship in Integrative Medicine at Beth Israel Deaconess Medical Center in 2012, and receiving
a Master’s in Public Health from Harvard T.H. Chan School of Public Health in 2014. Dr. Hall was the 2015
Harvard Catalyst Program for Faculty Development and Diversity Inclusion (PPFDD) faculty fellow and is the
2019 BWH Minority Faculty Career Development Awardee. Dr. Hall’s recent research has focused on
David Badesch catechol-O-methyltransferase (COMT), an enzyme that metabolizes catecholamines and estrogen and has
Presentation: // A study of sotatercept for the treatment of pulmonary arterial hypertension pleiotropic effects in a broad set of diseases and treatments, including cardiovascular disease and cancer.
(PULSAR, NCT03496207) Among her accomplishments is a landmark paper identifying COMT as one of the first genetic markers of
Sponsor: // Acceleron placebo response, a publication in JCI Insight on the placebo genetic network or placebome. She was recently
Talk: // 15:40 - 16:00 BST awarded a Radcliffe Exploratory Program grant which supported the groundbreaking Placebome in Clinical
Q&A: // 16:00 - 16:20 BST Trials and Medicine Conference in 2019. Her research has been the focus of numerous articles including
features on BBC and in Science, The Atlantic, New York Times, The Economist and Discover magazines.
Dr. Badesch is a Professor of Medicine, in the Divisions of Pulmonary Sciences & Critical Care Medicine, Dr. Hall also has a Masters in Documentary Film from Emerson College.
and Cardiology, and Director of the Pulmonary Hypertension Program, at the University of Colorado.
He has collaborated with dedicated clinical scientists on the Steering Committees (national and international)
of clinical trials and registries conducted in the field of pulmonary hypertension. Dr. Badesch has authored or
co-authored papers describing the results of clinical trials in the field, in the Annals of Internal Medicine, New
England Journal of Medicine, Lancet, Journal of the American College of Cardiology, and CHEST. He has served
as Chair of the Scientific Leadership Council of the Pulmonary Hypertension Association (PHA), Chair of the
Pulmonary Circulation Assembly of the American Thoracic Society (ATS), and as a member the PHA and ATS
Board(s) of Directors, as well as on the ATS Planning and Education Committees. Dr. Badesch helped to lead
development of the ACCP/CHEST Medical Therapy Guidelines in 2004, and the updates to those guidelines
published in 2007, 2014, and 2019. He received the Outstanding Physician Award from the PHA in 2002, the
Outstanding Physician Award from the Colorado Thoracic Society in 2014, was inducted into the Colorado
Pulmonary Hall of Fame in 2014, and received the American Thoracic Society Public Advisory Roundtable
William J. Martin II Distinguished Achievement Award in 2015. He has been listed among the Best Doctors in
America 2001-present, and is a Distinguished Advisor to the Pulmonary Hypertension Association’s Scientific
Leadership Council. Dr. Badesch has also been an active member of the community, leading an effort to make
all public schools in Colorado tobacco-free. In recognition of his service, he has received the CHEST
Foundation’s Community Service Award (one of the first two recipients, in 1998). More recently, he has assisted
in the care of patients with pulmonary hypertension in South Africa, as well as the development of clinical
guidelines, a registry, and centers for pulmonary hypertension care there.
PVRI
Pulmonary Vascular
Research Institute
Our moderators during the live webinar on
29 June 2020 are...
D D S 2020
Paul Hassoun Allan Lawrie
Dr Paul M Hassoun is a Professor of Medicine at the Johns Hopkins University School of Medicine in the Allan Lawrie is a Professor of Translational
USA. His areas of clinical expertise include pulmonary disease and critical care medicine. Cardiopulmonary Science and British Heart
Dr Hassoun earned his MD from the Faculté de Médecine Lariboisière-Saint Louis (Paris VII, France) and Foundation Senior Basic Science Research
completed a residency in Internal Medicine at Brigham and Women’s Hospital and a Pulmonary and Critical Fellow in the Department of Infection,
DIGITAL
Care fellowship at Massachusetts General Hospital, both at Harvard Medical School, Boston MA. Immunity & Cardiovascular Disease at the
University of Sheffield.
Dr Hassoun serves as the Director of the Pulmonary Hypertension Programme, a large clinical programme
dedicated to the diagnosis and treatment, in a multidisciplinary fashion, of all five disease groups from the Allan’s research has focused on identifying a key
World Classification of PH. role for osteoprotegerin/TRAIL pathway in the
pathogenesis of PAH. Supported by Fellowships and
Over the past two decades, Dr Hassoun has led programmatic efforts for clinical and basic research in PH.
grants from the MRC and BHF he has recently
Dr Hassoun’s research interests include pulmonary arterial hypertension (PAH) with a focus on highly
developed a novel human therapeutic antibody targeting
translational research to understand the complex pathobiology of scleroderma-associated PAH, and acute
this pathway.
lung injury. He is a member of numerous professional organisations, including the American Thoracic Society,
the European Respiratory Society, and the American Heart Association. Allan also works closely with clinical colleagues locally,
nationally and internationally to identify biomarkers and utilise
Dr Hassoun served as PVRI President during 2018/19.
multi-omic approaches for molecular phenotyping, identifying
novel disease mechanisms and drug targets.
Anna Hemnes
Associate Professor and Assistant Director Pulmonary Vascular Centre, Vanderbilt University Medical
Centre, USA.
Dr Anna Hemnes is a translational physician-scientist with a research focus on the role of altered metabolism
in pulmonary vascular disease. Her basic research is on the effect of BMPR2 mutation on insulin-mediated
intracellular signalling in the pulmonary vasculature and the right ventricle.
Dr Hemnes’ clinical research interests include the role of insulin resistance and metabolic syndrome in human
pulmonary vascular disease with a focus on genetic susceptibility to these conditions, and deep molecular
phenotyping of pulmonary vascular disease.
Scientific Programme We are extremely grateful to all the presenters who
have agreed to provide a recording of their talk.
These presentations will be released from
Featured presentation releases...
24-28 June and can be accessed via
https://pvrinstitute.org/en/professionals/learning/
24-28 June 2020
24 June
D D S 2020
Tamoxifen therapy to treat pulmonary arterial hypertension (T3PAH) (NCT03528902)
Presenter: // Eric Austin VANDERBILT UNIVERSITY, USA
Sponsor: // Vanderbilt University Medical Center
IV iron replacement for iron deficiency in idiopathic pulmonary arterial hypertension (IPAH) patients
DIGITAL
(NCT01447628)
Presenter: // Luke Howard IMPERIAL COLLEGE LONDON, UK
Sponsor: // Imperial College London
25 June
Right heart III Study: Right ventricular haemodynamic evaluation and response to treatment
(NCT03362047)
Presenter: // Khodr Tello JUSTUS-LIEBIG-UNIVERSITY GIESSEN, GERMANY
Sponsor: // Justus-Liebig-University Giessen
Actigraphy as a new endpoint in PAH trials
Presenter: // Ioana Preston TUFTS UNIVERSITY SCHOOL OF MEDICINE, USA
26 June
BPA: Where does it come from, where are we and where are we going?
Presenter: // Hiromi Matsubara NATIONAL HOSPITAL ORGANIZATION OKAYAMA MEDICAL CENTER, JAPAN
A novel unidirectional-valved shunt approach for end-stage pulmonary arterial hypertension:
Early experience in adolescents and adults
Presenter: // Erika Rosenzweig COLUMBIA UNIVERSITY MEDICAL CENTER, USA
Sponsor: // Columbia University
27 June
PADN-5: Pulmonary arterial denervation in patients with pulmonary hypertension associated with left heart
failure (NCT02220335)
Presenter: // Shao-Liang Chen NANJING FIRST HOSPITAL, NANJING MEDICAL UNIVERSITY, CHINA
Sponsor: // Nanjing Healthy Bureau & National Science Foundation of China
ABI-009, an mToR Inhibitor, for patients with severe pulmonary arterial hypertension (NCT02587325)
Presenter: // Ronald Oudiz HARBOR-UCLA FACULTY PRACTICE PLAN, USA
Sponsor: // Aadi, LLC
28 June
Implantable devices to improve pulmonary circulation compliance
Presenters: // John Scandurra ARIA CV, USA & Irene Lang MEDICAL UNIVERSITY OF VIENNA, AUSTRIA
Sponsor: // Aria CV
Efficacy and safety of initial triple oral versus initial double oral combination therapy in patients with newly
diagnosed pulmonary arterial hypertension: Results of the randomised controlled TRITON study (NCT02558231).
Presenter: // Kelly Chin UT SOUTHWESTERN, USA
Sponsor: // Actelion
Scientific Programme
We are anticipating a very large audience for this event.
If not all questions can be answered on the day, please be rest
Our live webinar...
assured that all comments, questions and answers will be
published and circulated to all participants after the webinar.
29 June 2020
NOTE: All times indicated are British Summer Time (BST)
15:00
D D S 2020
Clinical study of inhaled GB002 for treatment of WHO Group I pulmonary arterial
hypertension (PAH) (NCT03926793) 15:00 - 15:20 BST
DIGITAL
Presenter: // Ardeschir Ghofrani JUSTUS-LIEBIG-UNIVERSITY GIESSEN, GERMANY
Sponsor: // Gossamer Bio
Q&A session 15:20 - 15:40 BST
15:40
A study of sotatercept for the treatment of pulmonary arterial hypertension
(PULSAR, NCT03496207) 15:40 - 16:00 BST
Presenter: // David Badesch UNIVERSITY OF COLORADO, USA
Sponsor: // Acceleron
Q&A session 16:00 - 16:20 BST
16:20
Pharmacogenomics and placebo response in a randomised clinical trials 16:20 - 16:40 BST
Presenter: // Kathryn Hall BRIGHAM AND WOMEN’S HOSPITAL, HARVARD MEDICAL SCHOOL, USA
Q&A session 16:40 - 17:00 BST
Step into the PVRI
Digital Clinic...
...and claim CME credits.
PVRI
Pulmonary Vascular
Research Institute
www.pvrinstitute.org
The PVRI is a Registered Charity in the UK, No: 1127115.
Disclaimer: This programme and its contents are correct at the time of printing.
You can also read
